NL-OMON35950已完成不适用
A DOUBLE-BLIND, ASCENDING SINGLE AND MULTIPLE DOSE, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND FOOD EFFECT STUDY OF EVP 0962 IN HEALTHY VOLUNTEERS - EVP-0962 single and multiple ascending dose study
EnVivo Pharmaceuticals, Inc.0 个研究点目标入组 84 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age : SAD part (Groups 1-3) and MAD part (Groups 4-7): 18-65 years, inclusive; MAD part (Group 8): 66-80 years
- •BMI : 18.0 * 28.0 kg/m2, inclusive
- •Gender : healthy male or female subjects; female subjects must be of non-childbearing potential (either surgically sterilized or at least 1 year post-menopausal)
排除标准
- •Suffering from : hepatitis B. cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of the study. In case of donating blood or significant loss of blood within 60 days of the start of drug dosing.
研究者
相似试验
已完成
不适用
A DOUBLE-BLIND, ASCENDING SINGLE AND MULTIPLE DOSE, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND FOOD EFFECT STUDY OF EVP 6308 IN HEALTHY VOLUNTEERS.delusions10039628schizophreniaNL-OMON37679EnVivo Pharmaceuticals, Inc.70
招募中
1 期
An ascending, single and multiple dose(s), double-blind, randomized, placebo controlled study assessing the safety, tolerability, and pharmacokinetics of ov329 in healthy male and female participantsrare seizure disordersNeurological - EpilepsyACTRN12624000214538Ovid Therapeutics Australia Pty Ltd56
进行中（未招募）
不适用
ot applicableEUCTR2011-002665-38-GBAlmirall S.A.110
进行中（未招募）
1 期
A clinical study to assess the benefits of aclidinium bromide/formoterol fumarate (active treatment) compared with placebo (comparator) in lung volumes, exercise capacity and physical activity after 8-weeks of treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD). The study is randomised (equal chance of receiving active treatment or comparator) and double blind (neither patients nor the study doctor will know the treatment).Chronic obstructive pulmonary disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-005318-50-HUAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden268
进行中（未招募）
1 期
A clinical study to assess the benefits of aclidinium bromide/formoterol fumarate (active treatment) compared with placebo (comparator) in lung volumes, exercise capacity and physical activity after 8-weeks of treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD). The study is randomised (equal chance of receiving active treatment or comparator) and double blind (neither patients nor the study doctor will know the treatment).Chronic obstructive pulmonary disease (COPD)MedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-005318-50-ESAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden268